Prognostic Importance of C‐Reactive Protein in High Cardiovascular Risk Patients With Type 2 Diabetes Mellitus: The Rio de Janeiro Type 2 Diabetes Cohort Study

Background The prognostic value of C‐reactive protein ( CRP ) is controversial in type 2 diabetes mellitus. We aimed to assess it in a cohort of high cardiovascular risk diabetic patients. Methods and Results CRP was measured at baseline and during the second year of follow‐up in 616 patients. The primary end points were a composite of total fatal and nonfatal cardiovascular events ( CVE s), major CVE s, and all‐cause and cardiovascular mortalities. Association between baseline and second‐year CRP with end points were evaluated by multivariable Cox survival analyses. Baseline median CRP was 2.8 mg/L (interquartile range: 1.2–6.0 mg/L), and 47.8% of the patients either increased or persisted with high CRP levels during the first 2 years of follow‐up. After a median follow‐up of 8.4 years, 131 total CVE s occurred (89 major CVE s), and 129 patients died (53 of cardiovascular causes). Baseline and second‐year CRP , analyzed as a continuous variable and dichotomized at >3.0 mg/L, were significantly associated with total and major CVE s occurrence (with adjusted hazard ratios between 1.22 and 1.34 for increments of 1‐ SD log of continuous CRP , and between 1.47 and 1.89 for dichotomized CRP ), but not with mortality. Additionally, increasing CRP levels or persisting with high levels were associated with a 1.84 (95% CI : 1.10–3.06) excess risk of major CVE s, independent of baseline CRP values. Conclusions Baseline and serial changes in CRP levels provide cardiovascular risk prediction independent of standard risk factors and glycemic control, and may be useful to refine cardiovascular risk stratification in high‐risk patients with type 2 diabetes mellitus.